 IUC-4 is a novel IIB3 antagonist being developed as a subcutaneous SC, administered first point of medical contact treatment for ST segment elevation myocardial infarction, STEMI. In animal studies, it showed good safety profile and was able to reach dose-dependent peak levels within 5 to 15 minutes after administration. It also demonstrated significant inhibition of ADP-induced platelet aggregation, which correlated closely with its ability to block IIB3 receptors. This article was authored by Spandana Vutukuri, Jihong Lee, Mark Nedelman, and others.